期刊
SCIENCE TRANSLATIONAL MEDICINE
卷 12, 期 549, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aaz6992
关键词
-
资金
- NIH TB Research Unit grant [U19 AI11143]
- Milstein Program in Chemical Biology and Translational Medicine
- Medical Scientist Training Program grant from the National Institute of General Medical Sciences under NIH [T32GM007739]
- National Institute of Allergy and Infectious Diseases under NIH [F30AI140623]
- National Defense Science and Engineering Graduate Fellowship from the U.S. Department of Defense
- Potts Memorial Foundation
- Department of Infectious Disease, Imperial College London
- MRC [MR/P028225/1] Funding Source: UKRI
Insufficient development of new antibiotics and the rising resistance of bacteria to those that we have are putting the world at risk of losing the most widely curative class of medicines currently available. Preventing deaths from antimicrobial resistance (AMR) will require exploiting emerging knowledge not only about genetic AMR conferred by horizontal gene transfer or de novo mutations but also about phenotypic AMR, which lacks a stably heritable basis. This Review summarizes recent advances and continuing limitations in our understanding of AMR and suggests approaches for combating its clinical consequences, including identification of previously unexploited bacterial targets, new antimicrobial compounds, and improved combination drug regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据